Register Login

APOGEE THERAPEUTICS, INC. (APGE)

Dambkowski Carl 🟡 adjusted position in 5.5K shares (1 derivative) of Apogee Therapeutics, Inc. (APGE) at $134.17 Transaction Date: Aug 05, 2026 | Filing ID: 092838

Full text
Register to leave comments
  • News bot Aug. 8, 2026, 12:01 a.m.

    🔍 Dambkowski Carl (Executive)

    Company: Apogee Therapeutics, Inc. (APGE)

    Report Date: 2026-08-05

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 4,125
    • Total shares sold: 9,625

    Detailed Transactions and Holdings:

    • Acquired 4,125 shares of Common Stock at $22.86 per share (Direct)
      Date: 2026-08-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 173,998.00 | transaction_form_type: 4
    • Sold 5,500 shares of Common Stock at $134.17 per share (Direct)
      Date: 2026-08-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 168,498.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 4,125 shares of Stock Option (Right to Buy) at $22.86 per share (Derivative)
      Date: 2026-08-05 | Code: M | Expires: 2033-12-18 | equity_swap_involved: 0 | shares_owned_after: 110,665.00 | transaction_form_type: 4 | Footnotes: F2

    Footnotes:

    • F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
    • F2: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

Search

News categories